Related references
Note: Only part of the references are listed.Quantitative Systems Toxicology Modeling Predicts that Reduced Biliary Efflux Contributes to Tolvaptan Hepatotoxicity
James J. Beaudoin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
Vicente E. Torres et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)
Safety Profile of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
Ioannis Bellos
Therapeutics and Clinical Risk Management (2021)
Next-Generation DILI Biomarkers: Prioritization of Biomarkers for Qualification and Best Practices for Biospecimen Collection in Drug Development
Sharin E. Roth et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Polycystic liver disease: Classification, diagnosis, treatment process, and clinical management
Ze-Yu Zhang et al.
WORLD JOURNAL OF HEPATOLOGY (2020)
EASL Clinical Practice Guidelines: Drug-induced liver injury
Raul J. Andrade et al.
JOURNAL OF HEPATOLOGY (2019)
Altered Expression and Function of Hepatic Transporters in a Rodent Model of Polycystic Kidney Disease
Jacqueline Bezencon et al.
DRUG METABOLISM AND DISPOSITION (2019)
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial
Vicente E. Torres et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2018)
Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors
Jeffrey L. Woodhead et al.
TOXICOLOGICAL SCIENCES (2017)
Drug Rechallenge Following Drug-Induced Liver Injury
Christine M. Hunt et al.
HEPATOLOGY (2017)
Associations of Drug Lipophilicity and Extent of Metabolism with Drug-Induced Liver Injury
Kristin McEuen et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
Vicente E. Torres et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Drug-Induced Liver Injury: Advances in Mechanistic Understanding That Will Inform Risk Management
M. Mosedale et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications
Lily Dara et al.
LIVER INTERNATIONAL (2016)
Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and Metabolites: Contributing Factors to Drug-Induced Liver Injury?
Jason R. Slizgi et al.
TOXICOLOGICAL SCIENCES (2016)
Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2016
Fouad T. Chebib et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2016)
Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial
Vicente E. Torres et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
A Model to predict severity of drug-induced liver injury in humans
Minjun Chen et al.
HEPATOLOGY (2016)
Can Rechallenge Be Done Safely After Mild or Moderate Drug-Induced Liver Injury?
John R. Senior
HEPATOLOGY (2016)
Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database
Paul B. Watkins et al.
DRUG SAFETY (2015)
Evolution of the Food and Drug Administration Approach to Liver Safety Assessment for New Drugs: Current Status and Challenges
John R. Senior
DRUG SAFETY (2014)
Causality Assessment for Suspected DILI During Clinical Phases of Drug Development
Arie Regev et al.
DRUG SAFETY (2014)
Human Drug-Induced Liver Injury Severity Is Highly Associated With Dual Inhibition of Liver Mitochondrial Function and Bile Salt Export Pump
Michael D. Aleo et al.
HEPATOLOGY (2014)
Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function
Susan E. Shoaf et al.
KIDNEY INTERNATIONAL (2014)
Drug-Induced Liver Injury
Michael D. Leise et al.
MAYO CLINIC PROCEEDINGS (2014)
High Lipophilicity and High Daily Dose of Oral Medications Are Associated With Significant Risk for Drug-Induced Liver Injury
Minjun Chen et al.
HEPATOLOGY (2013)
Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects
Susan E. Shoaf et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
Vicente E. Torres et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A pre-marketing ALT signal predicts post-marketing liver safety
Cynthia A. Moylan et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2012)
Case Definition and Phenotype Standardization in Drug-Induced Liver Injury
G. P. Aithal et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Evaluation of Drug-Induced Serious Hepatotoxicity (eDISH) Application of this Data Organization Approach to Phase III Clinical Trials of Rivaroxaban after Total Hip or Knee Replacement Surgery
Paul B. Watkins et al.
DRUG SAFETY (2011)
Standardization of nomenclature and causality assessment in drug-induced liver injury: Summary of a clinical research workshop
Robert J. Fontana et al.
HEPATOLOGY (2010)
Causality Assessment in Drug-Induced Liver Injury Using a Structured Expert Opinion Process: Comparison to the Roussel-Uclaf Causality Assessment Method
Don C. Rockey et al.
HEPATOLOGY (2010)
Monitoring for Hepatotoxicity: What Is the Predictive Value of Liver Function Tests?
J. R. Senior
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Drug-Induced Liver Injury Network (DILIN) Prospective Study Rationale, Design and Conduct
Robert J. Fontana et al.
DRUG SAFETY (2009)
Epidemiology of Idiosyncratic Drug-Induced Liver Injury
Lauren N. Bell et al.
SEMINARS IN LIVER DISEASE (2009)
Tolvaptan.: Treatment of heart failure, vasopressin V2 antagonist.
LA Sorbera et al.
DRUGS OF THE FUTURE (2002)
Share Paper
